Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes

• Published in: Annals of internal medicine Vol. 167; no. 7; p. 493
• Main Authors: Chamberlain, James J, Kalyani, Rita Rastogi, Leal, Sandra, Rhinehart, Andrew S, Shubrook, Jay H, Skolnik, Neil, Herman, William H
• Format: Journal Article
• Language: English
• Published: United States American College of Physicians 03-10-2017
• Subjects: Blood Glucose - analysis; Blood Glucose Self-Monitoring; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Disease management; Evidence-based medicine; Glycated Hemoglobin A - analysis; Humans; Hypoglycemia - chemically induced; Hypoglycemia - classification; Hypoglycemic Agents - adverse effects; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Insulin - adverse effects; Insulin - pharmacokinetics; Insulin - therapeutic use; Islet Amyloid Polypeptide - therapeutic use; Liraglutide - therapeutic use; Medical diagnosis; Metformin - therapeutic use
• ISSN: 0003-4819; 1539-3704
• DOI: 10.7326/m17-1259

The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes.
For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions.
This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.